Cargando…

Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis

In systemic mastocytosis (SM), qualitative and serial quantitative assessment of the KIT D816V mutation is of diagnostic and prognostic relevance. We investigated peripheral blood and bone marrow samples of 161 patients (indolent SM (ISM), n = 40; advanced SM, AdvSM, n = 121) at referral and during...

Descripción completa

Detalles Bibliográficos
Autores principales: Naumann, Nicole, Lübke, Johannes, Baumann, Sofie, Schwaab, Juliana, Hoffmann, Oliver, Kreil, Sebastian, Dangelo, Vito, Reiter, Lukas, Bugert, Peter, Kristensen, Thomas, Sotlar, Karl, Haselmann, Verena, Schneider, Sven, Metzgeroth, Georgia, Weiss, Christel, Popp, Henning D., Fabarius, Alice, Hofmann, Wolf-Karsten, Cross, Nicholas C. P., Reiter, Andreas, Jawhar, Mohamad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961551/
https://www.ncbi.nlm.nih.gov/pubmed/33806359
http://dx.doi.org/10.3390/ijms22052562
_version_ 1783665285545328640
author Naumann, Nicole
Lübke, Johannes
Baumann, Sofie
Schwaab, Juliana
Hoffmann, Oliver
Kreil, Sebastian
Dangelo, Vito
Reiter, Lukas
Bugert, Peter
Kristensen, Thomas
Sotlar, Karl
Haselmann, Verena
Schneider, Sven
Metzgeroth, Georgia
Weiss, Christel
Popp, Henning D.
Fabarius, Alice
Hofmann, Wolf-Karsten
Cross, Nicholas C. P.
Reiter, Andreas
Jawhar, Mohamad
author_facet Naumann, Nicole
Lübke, Johannes
Baumann, Sofie
Schwaab, Juliana
Hoffmann, Oliver
Kreil, Sebastian
Dangelo, Vito
Reiter, Lukas
Bugert, Peter
Kristensen, Thomas
Sotlar, Karl
Haselmann, Verena
Schneider, Sven
Metzgeroth, Georgia
Weiss, Christel
Popp, Henning D.
Fabarius, Alice
Hofmann, Wolf-Karsten
Cross, Nicholas C. P.
Reiter, Andreas
Jawhar, Mohamad
author_sort Naumann, Nicole
collection PubMed
description In systemic mastocytosis (SM), qualitative and serial quantitative assessment of the KIT D816V mutation is of diagnostic and prognostic relevance. We investigated peripheral blood and bone marrow samples of 161 patients (indolent SM (ISM), n = 40; advanced SM, AdvSM, n = 121) at referral and during follow-up for the KIT D816V variant allele frequency (VAF) at the DNA-level and the KIT D816V expressed allele burden (EAB) at the RNA-level. A round robin test with four participating laboratories revealed an excellent correlation (r > 0.99, R(2) > 0.98) between three different DNA-assays. VAF and EAB strongly correlated in ISM (r = 0.91, coefficient of determination, R(2) = 0.84) but only to a lesser extent in AdvSM (r = 0.71; R(2) = 0.5). However, as compared to an EAB/VAF ratio ≤2 (cohort A, 77/121 patients, 64%) receiver operating characteristic (ROC) analysis identified an EAB/VAF ratio of >2 (cohort B, 44/121 patients, 36%) as predictive for an advanced phenotype and a significantly inferior median survival (3.3 vs. 11.7 years; p = 0.005). In terms of overall survival, Cox-regression analysis was only significant for the EAB/VAF ratio >2 (p = 0.006) but not for VAF or EAB individually. This study demonstrates for the first time that the transcriptional activity of KIT D816V may play an important role in the pathophysiology of SM.
format Online
Article
Text
id pubmed-7961551
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79615512021-03-17 Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis Naumann, Nicole Lübke, Johannes Baumann, Sofie Schwaab, Juliana Hoffmann, Oliver Kreil, Sebastian Dangelo, Vito Reiter, Lukas Bugert, Peter Kristensen, Thomas Sotlar, Karl Haselmann, Verena Schneider, Sven Metzgeroth, Georgia Weiss, Christel Popp, Henning D. Fabarius, Alice Hofmann, Wolf-Karsten Cross, Nicholas C. P. Reiter, Andreas Jawhar, Mohamad Int J Mol Sci Article In systemic mastocytosis (SM), qualitative and serial quantitative assessment of the KIT D816V mutation is of diagnostic and prognostic relevance. We investigated peripheral blood and bone marrow samples of 161 patients (indolent SM (ISM), n = 40; advanced SM, AdvSM, n = 121) at referral and during follow-up for the KIT D816V variant allele frequency (VAF) at the DNA-level and the KIT D816V expressed allele burden (EAB) at the RNA-level. A round robin test with four participating laboratories revealed an excellent correlation (r > 0.99, R(2) > 0.98) between three different DNA-assays. VAF and EAB strongly correlated in ISM (r = 0.91, coefficient of determination, R(2) = 0.84) but only to a lesser extent in AdvSM (r = 0.71; R(2) = 0.5). However, as compared to an EAB/VAF ratio ≤2 (cohort A, 77/121 patients, 64%) receiver operating characteristic (ROC) analysis identified an EAB/VAF ratio of >2 (cohort B, 44/121 patients, 36%) as predictive for an advanced phenotype and a significantly inferior median survival (3.3 vs. 11.7 years; p = 0.005). In terms of overall survival, Cox-regression analysis was only significant for the EAB/VAF ratio >2 (p = 0.006) but not for VAF or EAB individually. This study demonstrates for the first time that the transcriptional activity of KIT D816V may play an important role in the pathophysiology of SM. MDPI 2021-03-04 /pmc/articles/PMC7961551/ /pubmed/33806359 http://dx.doi.org/10.3390/ijms22052562 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Naumann, Nicole
Lübke, Johannes
Baumann, Sofie
Schwaab, Juliana
Hoffmann, Oliver
Kreil, Sebastian
Dangelo, Vito
Reiter, Lukas
Bugert, Peter
Kristensen, Thomas
Sotlar, Karl
Haselmann, Verena
Schneider, Sven
Metzgeroth, Georgia
Weiss, Christel
Popp, Henning D.
Fabarius, Alice
Hofmann, Wolf-Karsten
Cross, Nicholas C. P.
Reiter, Andreas
Jawhar, Mohamad
Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis
title Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis
title_full Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis
title_fullStr Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis
title_full_unstemmed Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis
title_short Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis
title_sort adverse prognostic impact of the kit d816v transcriptional activity in advanced systemic mastocytosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961551/
https://www.ncbi.nlm.nih.gov/pubmed/33806359
http://dx.doi.org/10.3390/ijms22052562
work_keys_str_mv AT naumannnicole adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis
AT lubkejohannes adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis
AT baumannsofie adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis
AT schwaabjuliana adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis
AT hoffmannoliver adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis
AT kreilsebastian adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis
AT dangelovito adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis
AT reiterlukas adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis
AT bugertpeter adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis
AT kristensenthomas adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis
AT sotlarkarl adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis
AT haselmannverena adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis
AT schneidersven adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis
AT metzgerothgeorgia adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis
AT weisschristel adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis
AT popphenningd adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis
AT fabariusalice adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis
AT hofmannwolfkarsten adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis
AT crossnicholascp adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis
AT reiterandreas adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis
AT jawharmohamad adverseprognosticimpactofthekitd816vtranscriptionalactivityinadvancedsystemicmastocytosis